ZimVie (NASDAQ:ZIMV) Issues FY 2025 Earnings Guidance

ZimVie (NASDAQ:ZIMV) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 0.800-0.950 for the period, compared to the consensus EPS estimate of 0.750. The company issued revenue guidance of $445.0 million-$460.0 million, compared to the consensus revenue estimate of $458.0 million.

Analyst Ratings Changes

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of ZimVie in a research report on Thursday.

ZimVie Price Performance

NASDAQ:ZIMV traded down $0.40 during trading hours on Thursday, hitting $12.70. 25,836 shares of the stock traded hands, compared to its average volume of 248,272. The company has a market cap of $350.51 million, a price-to-earnings ratio of -0.99 and a beta of 2.10. ZimVie has a 1 year low of $12.68 and a 1 year high of $22.40. The stock has a 50 day moving average price of $13.77 and a 200 day moving average price of $14.79. The company has a quick ratio of 1.38, a current ratio of 1.94 and a debt-to-equity ratio of 0.57.

ZimVie (NASDAQ:ZIMV) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.02. ZimVie had a positive return on equity of 2.90% and a negative net margin of 77.31%. The business had revenue of $111.52 million for the quarter, compared to analysts’ expectations of $113.67 million. Sell-side analysts forecast that ZimVie will post 0.6 EPS for the current fiscal year.

ZimVie Company Profile

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.